Analysts Conflicted on These Healthcare Names: Novan (NASDAQ: NOVN) and Avrobio (NASDAQ: AVRO)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Novan (NOVNResearch Report) and Avrobio (AVROResearch Report).

Novan (NOVN)

H.C. Wainwright analyst Oren Livnat maintained a Buy rating on Novan yesterday and set a price target of $2.00. The company’s shares closed last Tuesday at $1.29.

According to TipRanks.com, Livnat is a 4-star analyst with an average return of 9.8% and a 48.8% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Verrica Pharmaceuticals, and Taiwan Liposome Company.

Currently, the analyst consensus on Novan is a Moderate Buy with an average price target of $2.50, which is a 96.9% upside from current levels. In a report issued on April 22, Roth Capital also initiated coverage with a Buy rating on the stock with a $3.00 price target.

See today’s analyst top recommended stocks >>

Avrobio (AVRO)

In a report issued on May 3, Mani Foroohar from Leerink Partners maintained a Hold rating on Avrobio, with a price target of $10.00. The company’s shares closed last Tuesday at $8.98.

According to TipRanks.com, Foroohar has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -5.5% and a 50.8% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Adverum Biotechnologies, and Rocket Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Avrobio with a $18.75 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.